SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Avience Biomedicals Ltd (AVIENCE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AVIENCE Medical Equipment/Supplies/Accessories | Small Cap | Avience Biomedicals Share Price

BSE Share Price
Not Listed

Avience Biomedicals Ltd (AVIENCE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AVIENCE Medical Equipment/Supplies/Accessories | Small Cap | Avience Biomedicals Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹185 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹9.4
TTM Sales
₹28.9 Cr.
Book Value per Share
₹40.1
P/E Ratio
36.11
Lower than its 5-year historical median
Industry PE
112.3
Price to Book (P/B)
8.44
Lower than its 5-year historical median
Price to Sales (P/S)
6.42
Lower than its 5-year historical median
EV/EBITDA
23.35
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
38.64%
Return on Capital Employed (ROCE)
31.63%
Return on Assets (ROA)
14.83%
Operating Profit Margin
26.6%
Net Profit Margin
17.77%
Gross Profit Margin
26.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
77.68%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
141.51%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
159.6%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹16 Cr.
Equity
₹5.5 Cr.
Face Value
₹10
All Time Low / High
- / -

Avience Biomedicals stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Avience Biomedicals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ21.4%20.6%30.4%31.6%-
Value Creation
Index ⓘ		0.50.51.21.3-

Growth Parameters ⓘ
Sales ⓘ10.210.916.328.929
Sales YoY Gr.-7.6%48.9%77.7%-
Adj EPS ⓘ2.72.2612.69.4
YoY Gr.--18.8%173.2%109.8%-
BVPS (₹) ⓘ10.612.418.450.940.1
Adj Net
Profit ⓘ		0.70.725.15
Cash Flow from Ops. ⓘ-21.60.23.2-
Debt/CF from Ops. ⓘ-1.31.733.44.3-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA41.7%77.7%
Adj EPS ⓘNANA67%109.8%
BVPSⓘNANA68.9%176.2%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		25.721.13938.320.6
Op. Profit
Mgn % ⓘ		1213.319.526.6NAN
Net Profit
Mgn % ⓘ		7.16.612.117.617.8
Debt to
Equity ⓘ		0.90.71.30.7-
Working Cap
Days ⓘ		02032262050
Cash Conv.
Cycle ⓘ		0132114900

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales10111629
Operating Expenses ⓘ + 991321
Manufacturing Costs0000
Material Costs881117
Employee Cost 0112
Other Costs ⓘ 1112
Operating Profit ⓘ 1138
Operating Profit Margin (%) 12.0%13.1%19.5%26.6%
Other Income ⓘ + 0001
Exceptional Items ⓘ 0000
Interest ⓘ 0001
Depreciation ⓘ 0001
Profit Before Tax ⓘ 1137
Tax ⓘ 0012
Profit After Tax 1125
PAT Margin (%) 7.1%6.5%12.2%17.8%
Adjusted EPS (₹)2.72.26.012.7
Dividend Payout Ratio (%)0%0%0%0%

Valuation of Avience Biomedicals - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 34621
Share Capital ⓘ 2334
Reserves ⓘ 11316
Debt +23713
Long Term Debt0016
Short Term Debt2267
Minority Interest0000
Trade Payables0145
Others Liabilities ⓘ 1285
Total Liabilities ⓘ 6102644

Fixed Assets

Net Fixed Assets ⓘ +1379
Gross Block13810
Accumulated Depreciation0011
CWIP ⓘ 0005
Investments ⓘ 0066
Inventories1488
Trade Receivables3229
Cash Equivalents 0005
Others Assets ⓘ 1233
Total Assets ⓘ 6102644

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + -2203
PBT ⓘ 1137
Adjustment ⓘ 0011
Changes in Working Capital ⓘ -30-3-4
Tax Paid ⓘ -0-0-0-1
Cash Flow From Investing Activity ⓘ + -1-2-4-8
Capex -1-2-4-8
Net Investments -0-0-0-0
Others ⓘ 0000
Cash Flow From Financing Activity ⓘ + 3049
Net Proceeds from Shares ⓘ 1104
Net Proceeds from Borrowing ⓘ 0015
Interest Paid ⓘ -0-0-0-1
Dividend Paid ⓘ 0000
Others ⓘ 2041
Net Cash Flow ⓘ -00-04

Financial Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)25.7120.6339.1938.64
ROCE (%)21.3520.5630.431.63
Asset Turnover Ratio1.661.360.910.83
PAT to CFO Conversion(x)-2200.6
Working Capital Days
Receivable Days9172.5047.5071.50
Inventory Days52.8083.80128.10101.10
Payable Days11.1035.2093.6097.60

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Avience Biomedicals Ltd FAQs

The current trading price of Avience Biomedicals on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Avience Biomedicals stood at ₹185.4 Cr

The latest P/E ratio of Avience Biomedicals as of 31-Dec-1969 is 36.11.

The latest P/B ratio of Avience Biomedicals as of 31-Dec-1969 is 8.44.

The 52-week high of Avience Biomedicals is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Avience Biomedicals is ₹28.89 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Avience Biomedicals Ltd is a below average quality company.

The key valuation ratios of Avience Biomedicals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Avience Biomedicals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Avience Biomedicals Ltd

Avience Biomedicals was incorporated as Avience Biomedicals Private Limited in December 23, 2019, in Delhi. Subsequently, the company was converted into a Public Limited Company pursuant to shareholders resolution passed at the Extra Ordinary General Meeting of the company held on June 26, 2024 and the name of the company was changed from ‘Avience Biomedicals Private Limited’ to ‘Avience Biomedicals Limited’ on September 03,2024.

The company is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices. The company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good-quality solutions. The company has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs. 

Being majorly into B2B and B2C market, its products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the company also act as distributors and traders of medical equipment. The company is an ISO 9001:2016, ISO 13485, ZED MSME Gold and Good Manufacturing Practice (GMP) certified organization.

Business area of the company 

The company is primarily engaged in the business of manufacturing and selling of medical consumables. Its diversified product portfolio can primarily be divided into two main categories -- Manufacturing of Medical Consumables and Distribution of branded equipment.

Products of the company

Reagents & Consumable

  • Biochemistry Reagents - for liver function tests (LFT), kidney function tests (KFT), lipid profiles, glucose tests, etc.
  • Haematology Reagents - for complete blood count (CBC), differential count, etc.
  • Immunoassay Reagents - for detecting hormones, infectious diseases, and tumour markers.
  • Consumables - cuvettes, pipette tips, test tubes, microplates, and filters.

Diagnostic Instruments & Equipment

  • Automated Biochemistry Analysers - fully or semi-automated systems.
  • Haematology Analysers - 3-part or 5-part differential systems.
  • Immunoassay Analysers - CLIA systems, ELISA readers and washers.
  • Molecular Diagnostic Instruments - PCR machines, thermocyclers.
  • Microbiology Instruments - incubators, autoclaves, colony counters.
  • Electrolyte Analyser - used to measure the concentration of electrolytes in biological fluids such as blood, serum, plasma, or urine.

History and milestones

  • 2020-21: Inauguration of Noida Factory.
  • 2020-21: Initiated E-Commerce Sales through Government e-Marketplace (GeM) OEM.
  • 2021-22: Tenfold increase in turnover during FY 2021-22.
  • 2021-22: The company obtained 4 manufacturing licenses.
  • 2022-23: The company received approval for 10 additional production licenses.
  • 2023-24: The company secured an allotment of commercial land measuring 2,100 square meters within the Medical Device Park, located in the Yamuna Expressway Industrial Development Area, at a nominal lease rate.
  • 2023-24: The company dispatched first export order.
  • 2023-24: The company successfully completed first export order to Somalia and entered the African continent.
  • 2023-24: The company received approval from the Ethiopian Food and Drug Authority (EFDA) to export its products.
  • 2023-24: The company received a large government supply order after winning a bid in Andhra Pradesh for Rs 82.05 lakh.
  • 2023-24: The WHO recognized the company’s manufacturing process as a Good Manufacturing Practice (GMP) for producing quality products that meet international quality standards.
  • 2023-24: The company secured MSME ZED Gold Certification.
  • 2023-24: The company received approval for 31 new production licenses.
  • 2024-25: The company laid foundation stone for the new large production facility at the Medical Device Park at Yamuna Expressway Industrial Development Area. 
  • 2024-25: The company became one of the few manufacturers in India to receive validation for the sickle cell test from ICMR.
  • 2024-25: The company obtained its first license for manufacturing hematology equipment in FY 2024-25.
  • 2024-25: The company transitioned to a public company, marking a significant milestone in its growth and expansion.
  • 2024-25: The company received approval for 32 new production licenses.
  • 2025-26: The company received approval for 11 new production licenses.
  • 2026-27: The company received approval for 10 new production licenses.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: